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CASE REPORT
A rare case of severe gastroenteritis caused 
by Aeromonas hydrophila after colectomy 
in a patient with anti-Hu syndrome: a case 
report
Michael Greiner1, Alexia Anagnostopoulos2, Daniel Pohl3, Reinhard Zbinden1 and Andrea Zbinden1*  
Abstract 
Background: Aeromonas hydrophila is a gram-negative facultative anaerobic coccobacillus, which is an environmen-
tal opportunistic pathogen. A. hydrophila are involved in several infectious diseases such as gastroenteritis, septicemia 
and wound infections. However, gastroenteritis caused by Aeromonas spp. are rare and the clinical relevance of Aero-
monas species in stool specimens is still under debate.
Case presentation: Our case concerns a 32-year-old woman who presented at hospital with a worsening watery 
diarrhea and fever requiring intensive care. A cholera-like illness was diagnosed. The patient had a past history of an 
anti-Hu syndrome with a myenteric ganglionitis. A molecular multiplex RT-PCR (QIAstat-Dx Gastrointestinal Panel, 
QIAGEN) covering a broad spectrum of diverse gastrointestinal pathogens performed directly from the stool was 
negative but the stool culture revealed growth of A. hydrophila. Further investigations of the A. hydrophila strain in cell 
cultures revealed the presence of a cytotoxic enterotoxin.
Conclusions: Although A. hydrophila rarely causes gastroenteritis, Aeromonas spp. should be considered as a causa-
tive agent of severe gastroenteritis with a cholera-like presentation. This case highlights the need to perform culture 
methods from stool samples when PCR-based methods are negative and gastrointestinal infection is suspected.
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Background
Aeromonas spp. can cause different clinical diseases 
especially in the immunocompromised host. The most 
common infection sites are wound infections, cellulitis, 
septicemia and urinary tract infections [1–4]. Gastro-
enteritis due to Aeromonas spp. is generally rare but has 
been described before in the literature [5–7]. The clinical 
presentation of gastroenteritis varies from mild diarrhea 
to shigella-like dysentery to severe cholera-like watery 
diarrhea [8].
Aeromonas spp. are gram-negative facultative anaer-
obes that are straight, coccobacillary to bacillary cells 
with rounded ends. Aeromonads usually are oxidase pos-
itive and display a fermentative metabolism of glucose. 
The organisms grow at a range of temperatures from 10 
to 42  °C [4]. The genus Aeromonas currently consists 
of 36 species, of which Aeromonas hydrophila subsp. 
hydrophila, Aeromonas caviae, Aeromonas dhakensis, 
Aeromonas veronii biovar sobria (formerly Aeromonas 
sobria) and Aeromonas trota are clinically most impor-
tant and have been isolated often from human feces [9].
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Aeromonads feature several virulence factors such as 
the cytotoxic enterotoxin (Act protein), which has hemo-
lytic, cytotoxic, and enterotoxic activities; type 3 secre-
tion systems and motility factors [10–13]. Enterotoxins 
play a relevant role in the pathogenesis of diarrhea and 
their effect is reproducible in animal models [14]. The 
cytotoxic enterotoxin Act was previously isolated and 
extensively characterized [15]. Recently, there were also 
two cytotonic enterotoxins described, a heat stable (Ast 
protein) and a heat labile enterotoxin (Alt protein) [16, 
17]. The presence of Ast and Alt cytotonic enterotox-
ins in Aeromonas spp. were associated with severe diar-
rhea in children, however, these toxins were found also 
in environmental strains [16]. To our knowledge, the 
enterotoxins are chromosomally encoded [10, 11, 18]; the 
role of plasmids are unknown with the exception of one 
reported case with evidence of a Shiga-like toxin 1 on a 
plasmid in strains of A. hydrophila [10–13].
The role of Aeromonas spp. as enteropathogen is still 
controversial [19]. We report on a case where severe 
watery diarrhea was caused by A. hydrophila resulting in 
intensive care medical occupancy. We investigated phe-
notypically whether the clinical strain isolated from feces 
produced a cytotoxic enterotoxin.
Case presentation
A 32-year-old female patient was admitted to hospital 
with somnolence, aggravation of her chronic diarrhea 
and fever. The patient had a complicated medical his-
tory of intestinal neuronopathy with recurrent pseudo-
obstructions due to myenteric ganglionitis. The patient 
had therefore undergone a hemicolectomy and perma-
nent jejuno-rectostomy. She then developed chronic 
diarrhea (3 to 4 times per day), which led to a chronic 
hyponatremia (125 mmol/l, normal value between 135–
145 mmol/l). Less than a month prior to hospital admis-
sion, anti-Hu antibodies were detected associated with 
paraneoplastic neurological syndromes [20, 21]. An anti-
Hu syndrome with sensory neuronopathy was diagnosed. 
Despite extensive diagnostics, no underlying malignan-
cies could be found. Immunosuppressive therapy had not 
yet been initiated.
One week before the current presentation at the hos-
pital, she developed fever, chills, abdominal pain and an 
increased stool frequency (up to 10 times a day). The diar-
rhea was of watery consistency without blood or mucus. 
She had no contact to animals and did not consume con-
taminated food. None of her social contacts had signs of 
infectious gastroenteritis. At the emergency room, she 
was febrile (39.5 °C) and abdominal examination revealed 
increased bowel sounds without tenderness on palpation. 
She was somnolent without focal neurological deficits. 
The laboratory studies showed elevated inflammatory 
markers (157  mg/L C-reactive protein, CRP, normal 
value < 5 mg/l), and a severe hyponatremia of 107 mmol/l 
(normal value between 135–145 mmol/l). No pathologi-
cal findings were seen on the computed tomography scan 
of the abdomen, especially no abscess or perforation. The 
results from a lumbar puncture were inconspicuous and 
ruled out an infection or inflammation.
The severity of the diarrhea as well as inflammatory 
markers (CRP max 543 mg/L, procalcitonin, 84.88 µg/L, 
normal value < 0.1  µg/L) increased quickly despite man-
agement in the intermediate care unit. The patient now 
lost up to 12 L stool per day and was admitted to the 
intensive care unit for further treatment. On gross exam-
ination, her stool was brown and watery. Cultures of the 
blood, urine and stool were collected and an empiric 
antibiotic treatment was initiated. With a suspected 
gastrointestinal focus antibiotic treatment consisted of 
piperacillin-tazobactam i.v. (4.5 g every 8 h) and vanco-
mycin p.o. (250 mg every 6 h). The blood and urine cul-
tures did not detect any bacterial growth. A molecular 
multiplex real-time RT-PCR test for detection of numer-
ous gastrointestinal pathogens (QIAstat-Dx Gastrointes-
tinal (GI) panel, QIAGEN, Hilden, Germany) performed 
directly from the stool was negative  (Table  1). The 
Clostridioides difficile glutamate dehydrogenase (GDH) 
antigen in the stool was positive, as tested by VIDAS C. 
difficile GDH assay (bioMerieux, France), but the toxin 
genes remained negative as tested by real-time PCR 
(GeneXpert, Xpert C. difficile BT assay, Cepheid, USA).
After 3 days of treatment without any improvement in 
the patient’s condition, the piperacillin-tazobactam and 
vancomycin was stopped and meropenem i.v (1 g every 
8 h) and metronidazol i.v. (500 mg every 8 h) was started 
instead.
For bacterial culture, the stool was incubated on Mac-
Conkey’s agar (Oxoid, UK), Columbia 5% sheep blood 
agar (bioMérieux, Marcy l’Etoile, France) and deoxycho-
late citrate agar (DCA, Oxoid, UK) at 37 ºC. After 24 h, 
bacterial growth appeared on the plates showing yellow 
sucrose fermenting colonies on the DCA plate. The colo-
nies were non-lactose fermenting on DCA and MacCo-
nkey’s agar. On the sheep blood agar, bacterial colonies 
showed a remarkable β-hemolysis. The catalase and oxi-
dase tests both were positive.
The bacteria were identified as A. hydrophila by the 
matrix-assisted laser desorption ionization-time of 
flight mass spectrometry (MALDI-TOF MS, Bruker 
Daltonik, Bremen, Germany; using the MALDI Bio-
typer version 7.0). The antimicrobial susceptibil-
ity testing was performed by disk diffusion test on 
Mueller–Hinton agar plates (MH, Becton Dickinson, 
Franklin Lakes, NJ) and revealed susceptibility to mero-
penem, cefepime, piperacillin-tazobactam, ceftriaxone, 
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Table 1 Pathogen targets of the QIAstat-Dx Gastrointestinal panel (QIAGEN)
Bacterial targets Viruses Parasites
Clostridioides difficile toxin A/B
Enteroaggregative E. coli (EAEC)
Enteropathogenic E. coli (EPEC)
Enterotoxigenic E. coli (ETEC)
Enteroinvasive E. coli (EIEC)/Shigella
Shiga-like toxin-producing E. coli (STEC)


















Table 2 Antimicrobial susceptibility testing of the A. hydrophila strain
S susceptible, I intermediate, R resistant, n.a. not available
a According to Clinical and Laboratory Standards Institute guidelines, M45 3rd edition
Antimicrobial agent Disk content (µg) Zone diameter 
(mm)
Interpretive categories and zone 
diameter  breakpointsa (mm)
Interpretation
S I R
Ampicillin 10 6 n.a n.a n.a Resistant
Amoxicillin-clavulanate 20/10 12 n.a n.a n.a Resistant
Piperacillin-tazobactam 100/10 23  ≥ 21 18–20  ≤ 17 Susceptible
Ceftriaxone 30 37  ≥ 23 20–22  ≤ 19 Susceptible
Cefepime 30 33  ≥ 25 19–24  ≤ 18 Susceptible
Meropenem 10 27  ≥ 23 20–22  ≤ 19 Susceptible
Nalidixic acid 30 31 n.a n.a n.a Susceptible
Trimethoprim-sulfamethoxazole 1.25/23.75 22  ≥ 16 11–15  ≤ 10 Susceptible
Amikacin 30 21  ≥ 17 15–16  ≤ 14 Susceptible
Fig. 1 Cytotoxic effects of A. hydrophila cultured supernatant in Vero cells A negative control with culture media, B cytotoxic damage of A. 
hydrophila after 1 day incubation exhibiting cell rounding C cytotoxic damage of A. hydrophila after 4 days incubation, indicating cellular 
vacuolation and monolayer destruction
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nalidixic acid, trimethoprim-sulfamethoxazole and 
amikacin  (Table  2). The strain was resistant to amoxi-
cillin and amoxicillin-clavulanate (Table 2)  Interpreta-
tive criteria according to the Clinical and Laboratory 
Standards Institute guidelines, M45 3rd edition, were 
applied.
After the identification of A. hydrophila, metronida-
zol was stopped and following a 10-day treatment with 
meropenem and intravenous fluid substitution, the 
patient recovered slowly and hospital discharge was 
possible. During the next visit, four weeks after dis-
charge, the patient presented without fever or abdom-
inal pain and the frequency of stool was again 3 to 4 
times per day.
To demonstrate whether the clinical A. hydrophila 
strain produced an enterotoxin, the A. hydrophila culture 
supernatant was analyzed for enterotoxic activity in cell 
cultures [22, 23]. The bacterial strain was cultivated in 
trypticase soy broth media (Becton Dickinson, USA). The 
culture supernatant was sterile filtered and inoculated in 
a confluent monolayer of Vero (African green monkey 
kidney) cell lines cultivated in tissue culture tubes with 
Eagle’s minimum essential medium (MEM, Dulbecco’s, 
bioswisstec AG, Schaffhausen, Switzerland). Then the 
tube was incubated at 37 °C in a 5%  CO2 incubator. Tryp-
ticase soy broth and MEM medium were used as nega-
tive controls. Cell monolayer morphology was observed 
using an inverted microscope. After 1 day, morphological 
alterations in Vero cells were observed inducing round-
ing, detachment, cellular vacuolation and monolayer 
destruction (Fig.  1). These observations were consistent 
with the alterations found in previous reports [22–24]. 
The negative culture controls did not show these modifi-
cations and displayed a confluent monolayer (Fig. 1). The 
presence of an enterotoxin with cytotoxic activity was 
suggested.
Discussion and conclusion
We reported a case of severe gastroenteritis due to A. 
hydrophila in a patient with an anti-Hu syndrome. The 
patient had chronic diarrhea after colectomy, which 
was exacerbated requiring intensive care. In the litera-
ture, severe gastroenteritis caused by Aeromonas spp. 
are described in immunocompromised individuals [25] 
and in patients with chronic inflammatory bowel disease 
[26]. In our case, the patient neither received immuno-
suppressive therapy nor other medications, which would 
increase the patient’s vulnerability to severe infection. 
The common differential diagnoses and other pathogens 
were excluded. To our knowledge, this is the first case of 
severe gastroenteritis due to A. hydrophila in a patient 
with anti-Hu syndrome.
Despite the association of anti-Hu antibodies with 
paraneoplastic syndromes, we did not find any underly-
ing tumour in our patient. In a study by Graus et  al., a 
number of patients with neurological paraneoplastic syn-
dromes and anti-Hu antibody positivity in the absence of 
any tumour were described [27]. In patients such as our 
patient, with chronic pseudo-obstructions and after ile-
ocoecal surgery, there is a change in the gastrointestinal 
microbiome [28, 29] and intestinal bacterial overgrowth 
is more prevalent [30, 31]. Additionally, there is some evi-
dence concerning an increased susceptibility to gastroin-
testinal infections in patients with a history of gut surgery 
[32]. Thus, chronic intestinal pseudo-obstructions might 
be a possible explanation for our patient’s predisposition 
to severe gastroenteritis with A. hydrophila.
Although Aeromonas spp. most commonly are iso-
lated in the gastrointestinal tract, their role as an enter-
opathogen is still controversial [19]. The asymptomatic 
colonization in developed countries range from 0 to 
4% while the isolation rate from stool in persons with 
diarrheal illness ranges from 0.8 to 7.4% [16, 33]. Nev-
ertheless, there are many case reports that describe 
Aeromonas spp. as a causative enteropathogen [2]. In 
these reports, either an isolation of the microorganism 
in the feces or tissue samples was achieved or a positive 
serological response was present [2].
Beyond any doubt, evidence for local outbreaks is 
not sufficient, the literature is controversial [34, 35]. In 
our patient, the source of the infection was not found. 
Aeromonas spp. are environmental opportunistic path-
ogens that are inhabitants of aquatic ecosystems such 
as groundwater but might be present also in drinking 
water or dairy products [36].
In our case, bacterial stool cultures showed growth 
of A. hydrophila. In contrast, a fast multiplex RT-PCR 
covering a large panel of common gastrointestinal 
pathogens performed directly from the stool speci-
men remained negative. In the last years, numerous 
multiplex systems covering a broad range of gastroin-
testinal pathogens including bacteria, viruses and para-
sites appeared on the market. One such system is the 
QIAstat-Dx GI panel (QIAGEN), which is highlighted 
by a short turnaround time and was demonstrated to be 
a valuable tool for diagnosis of gastrointestinal patho-
gens [37]. Despite the advantages of molecular-based 
syndromic stool pathogen panels, rare pathogens such 
as Aeromonas spp. are not covered in most syndromic 
assays including the QIAstat-Dx GI panel [7] (Table 1). 
Because many laboratories are likely adopting these 
multiplex syndromic panels and no longer performing 
stool cultures, gastroenteritis caused by Aeromonas sp. 
might be underestimated.
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In our patient, the treatment with piperacillin-tazo-
bactam was not successful in alleviating the symptoms 
despite proven susceptibility in vitro. A possible explana-
tion might be the presence of chromosomally mediated 
β-lactamases such as the AmpC β-lactamase, missed by 
conventional phenotypic tests [38]. In a Korean study 
analyzing bacteremia caused by Aeromonas spp., cases 
were observed with a piperacillin-tazobactam resistance 
[39]. When meropenem was installed, clinical improve-
ment and laboratory response were observed. Never-
theless, the use of meropenem is controversial in the 
treatment of Aeromonas spp. due to the possibility of 
existing chromosomally mediated CphA carbapenemases 
[38]. Recent reports have identified carbapenemase-pro-
ducing Aeromonas spp. strains in clinical specimens [40].
The production of a cytotoxic enterotoxin is an impor-
tant virulence factor of A.°hydrophila [10, 22, 41]. The 
presence of the cytotoxic enterotoxin (Act protein) in 
clinical A.°hydrophila strains was previously shown to be 
associated with cytotoxicity in Vero cells thus indicating 
the potential of causing severe infections [42]. We have 
demonstrated the cytotoxic effect of the supernatant 
of the clinical A. hydrophila strain in Vero cells (Fig. 1). 
Therefore, we speculate that the clinical A. hydrophila 
strain was a cytotoxic enterotoxin producing strain, 
which was the cause for the severe clinical presenta-
tion. A limitation of our case report is, that we have not 
purified the toxin from the clinical A. hydrophila isolate 
and we have not proved the presence of the act gene, 
which encodes the cytotoxic enterotoxin, by molecular 
methods.
Although in some gastroenteritis cases the role of the 
isolation of Aeromonas spp. in stool specimens is dis-
cussed controversially, in our case, we have proof of the 
cytotoxic effect of the supernatant of the isolated A. 
hydrophila strain indicative of the presence of an enter-
otoxin and a remarkable clinical improvement in the 
patient’s condition after instalment of meropenem. The 
patient had a decrease in stool frequency, resolution 
of fever and the inflammatory parameter decreased 
significantly.
Aeromonas spp. should be considered in the differen-
tial diagnosis of acute gastroenteritis, which revealed 
broad spectrum multiplex-PCR negative results. Early 
diagnosis and initiation of appropriate therapy is cru-
cial for the clinical management. This case might serve 
as an argument that clinicians should consider also 
rare causative agents of gastroenteritis and highlights 
the need to perform culture methods in PCR-negative 
tested stool specimens where a clinical suspicion of 
gastrointestinal infection exists.
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